Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Femara Gets Priority Review; 1st-Line Use For AstraZeneca Arimidex

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis could see FDA action by January on its Femara sNDA for first-line treatment of advanced breast cancer in postmenopausal women. The application for the aromatase inhibitor was filed July 11 and received a priority review designation on Sept. 11, ten days after the approval of AstraZeneca’s AI Arimidex for the same indication.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel